Загрузка...
Apatinib as post second-line therapy in EGFR wild-type and ALK-negative advanced lung adenocarcinoma
In the absence of a driver mutation, chemotherapy is the standard treatment option as first- and second-line therapy for advanced non-small-cell lung cancer (NSCLC). Though a large number of patients are suitable for post second-line therapies, the quality and quantity of the available drugs in this...
Сохранить в:
| Опубликовано в: : | Onco Targets Ther |
|---|---|
| Главные авторы: | , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Dove Medical Press
2017
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5261838/ https://ncbi.nlm.nih.gov/pubmed/28176910 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S126613 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|